Serinus Biosciences

Serinus Bio is redefining precision in cancer therapeutics. Founded by MIT PhDs and supported by top investors, Serinus Bio is targeting the most pressing problem of cancer therapeutics – clinical translation. We design technology to determine how molecules function inside each tumor cell. By leveraging knowledge-primed models and cutting-edge cancer biology we are creating a new generation of AI for drug discovery. Our technology enables the development of drugs that work across a wide range of patient populations, override resistance mechanisms, and enable combinations by design.